On June 23, 2010
Mylan’s Revenge: New Suit Threatens to Double Patent Defense Costs for Big Pharma
Generic drug maker Mylan (MYL) has come up with a new tactic in the pharmaceutical patent wars: It’s alleging that AstraZeneca (AZN)’s legal defense of its Prilosec heartburn drug was a “sham” and “entirely devoid of merit.”
…
0 Comments